Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
International Journal of Clinical Oncology
Published in: International Journal of Clinical Oncology 2/2017

01-04-2017 | Original Article

Clinical outcomes of stage IV colorectal cancer after R0 resection: a multi-institutional retrospective analysis

Published in: International Journal of Clinical Oncology | Issue 2/2017

Login to get access

Abstract

Background

We analyzed the treatment outcomes after curative surgery for stage IV colorectal cancer to develop outcome-based follow-up protocols and treatment strategies.

Methods

This study was a multi-institutional retrospective analysis of treatment outcomes in patients who underwent R0 surgery for stage IV colorectal cancer.

Results

A total of 1133 patients, of whom 837 had recurrence, were included in this study. Recurrence occurred within 12 and 24 months after R0 surgery in 452 (54.0 %) and 652 (77.9 %) patients, respectively. Surgical resection was performed less frequently for recurrence within 12 months of R0 surgery than for recurrence after more than 12 months (p = 0.003). Prognosis was significantly better in patients who had recurrence more than 24 months after R0 surgery than in those who had recurrence within 24 months; this was not only for all patients but also specifically for patients with resection for recurrent disease. Recurrence was less frequent in patients who received preoperative chemotherapy than in patients who did not receive preoperative chemotherapy (p = 0.04). Of significance, fewer patients who received preoperative chemotherapy (57.5 %) had recurrence within 24 months compared with patients who did not receive preoperative chemotherapy (79.8 %) (p = 0.00001).

Conclusions

Intensive follow-up for at least 24 months was considered appropriate for monitoring disease recurrence after R0 surgery for stage IV colorectal cancer. In addition, preoperative chemotherapy contributed to improved outcomes.
Literature
1.
Nitzkorski JR, Farma JM, Watson JC et al (2012) Outcome and natural history of patients with stage IV colorectal cancer receiving chemotherapy without primary tumor resection. Ann Surg Oncol 19:379–383CrossRefPubMed
2.
Watanabe T, Itabashi M, Shimada Y et al (2015) Japanese Society for Cancer of the Colon and Rectum (JSCCR) Guidelines 2014 for treatment of colorectal cancer. Int J Clin Oncol 20:207–239CrossRefPubMedPubMedCentral
3.
4.
Mitry E, Fields AL, Bleiberg H et al (2008) Adjuvant chemotherapy after potentially curative resection of metastases from colorectal cancer: a pooled analysis of two randomized trials. J Clin Oncol 26:4906–4911CrossRefPubMed
5.
Parks R, Gonen M, Kemeny N et al (2007) Adjuvant chemotherapy improves survival after resection of hepatic colorectal metastases: analysis of data from two continents. J Am Coll Surg 204:753–761CrossRefPubMed
6.
Morise Z, Sugioka A, Fujita J et al (2006) Does repeated surgery improve the prognosis of colorectal liver metastases? J Gastrointest Surg 10:6–11CrossRefPubMed
7.
Oba M, Hasegawa K, Shindoh J et al (2016) Survival benefit of repeat resection of successive recurrences after the initial hepatic resection for colorectal liver metastases. Surgery 159:632–640CrossRefPubMed
8.
Nordlinger B, Sorbye H, Glimelius B et al (2013) Perioperative FOLFOX4 chemotherapy and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC 40983): long-term results of a randomised, controlled, phase 3 trial. Lancet Oncol 14:1208–1215CrossRefPubMed
9.
Van Cutsem E, Cervantes A, Nordlinger B et al (2014) Metastatic colorectal cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 25(Suppl 3):iii1–iii9CrossRefPubMed
10.
Japan Society for Cancer of the Colon and Rectum (ed) (2009) Japanese classification of colorectal carcinoma, 2nd English edition edn. Kanehara & Co, Tokyo
11.
Sobin L, Gospondarowicz M, Wittekind C, UICC International Union Against Cancer (2009) TNM classification of malignant tumors, 7th edn. Wiley, New York, pp 100–105
12.
Japan Society for Cancer of the Colon and Rectum (ed) (2014) Japanese classification of colorectal carcinoma, 2nd English edition edn. Kanehara & Co, Tokyo
13.
Wei AC, Greig PD, Grant D et al (2006) Survival after hepatic resection for colorectal metastases: a 10-year experience. Ann Surg Oncol 13:668–676CrossRefPubMed
14.
Fong Y, Fortner J, Sun RL et al (1999) Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer. Ann Surg 230:309–321CrossRefPubMedPubMedCentral
15.
Sato H, Maeda K, Kotake K et al (2015) Factors affecting recurrence and prognosis after R0 resection for colorectal cancer with peritoneal metastasis. J Gastroenterol 51:465–472CrossRefPubMed
16.
Watanabe K, Nagai K, Kobayashi A et al (2009) Factors influencing survival after complete resection of pulmonary metastases from colorectal cancer. Br J Surg 96:1058–1065CrossRefPubMed
17.
Ambiru S, Miyazaki M, Ito H et al (1998) Resection of hepatic and pulmonary metastases in patients with colorectal carcinoma. Cancer 82:274–278CrossRefPubMed
18.
Shah SA, Haddad R, Al-Sukhni W et al (2006) Surgical resection of hepatic and pulmonary metastases from colorectal carcinoma. J Am Coll Surg 202:468–475CrossRefPubMed
19.
Miller G, Biernacki P, Kemeny NE et al (2007) Outcomes after resection of synchronous or metachronous hepatic and pulmonary colorectal metastases. J Am Coll Surg 205:231–238CrossRefPubMed
20.
Meyerhardt JA, Mangu PB, Flynn PJ et al (2013) Follow-up care, surveillance protocol, and secondary prevention measures for survivors of colorectal cancer: American Society of Clinical Oncology clinical practice guideline endorsement. J Clin Oncol 31:4465–4470CrossRefPubMed
Metadata
Title
Clinical outcomes of stage IV colorectal cancer after R0 resection: a multi-institutional retrospective analysis
Publication date
01-04-2017
Published in
International Journal of Clinical Oncology / Issue 2/2017
Print ISSN: 1341-9625
Electronic ISSN: 1437-7772
DOI
https://doi.org/10.1007/s10147-016-1043-4

Other articles of this Issue 2/2017

International Journal of Clinical Oncology 2/2017 Go to the issue

Review Article

The effect of consolidation chemotherapy after concurrent chemoradiotherapy on the survival of patients with locally advanced non-small cell lung cancer: a meta-analysis

Original Article

Hyaluronic acid binding protein 1 overexpression is an indicator for disease-free survival in cervical cancer

Original Article

Multidisciplinary evaluation at baseline and during treatment improves the rate of compliance and efficacy of deferasirox in elderly myelodysplastic patients

Original Article

Quality-of-life evaluation during platinum-based neoadjuvant chemotherapies for urothelial carcinoma

Invited Review Article

Recent progress and perspectives on prostate cancer biomarkers

Original Article

Diagnostic value of tumor markers for lung adenocarcinoma-associated malignant pleural effusion: a validation study and meta-analysis
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits